Should the use of a brachytherapy boost affect the duration or use of ADT in intermediate or high risk prostate cancer?  

We traditionally think of 4-6 mo ADT for intermediate risk, and 18-36 mo ADT for high risk men treated with EBRT (whether dose escalated or not). For high risk men in our practice, I have usually recommended 28 mo (from RTOG 9202) ADT as a standard. I do think it is fair to consider a course <28 ...

@Stanley Liauw has summarized the issues well. My overall sense is the main benefit of ADT in combination with RT is on local disease. So, in the setting of a brachy boost, I generally use NO ADT in intermediate risk patients as well as the low end of high risk (e.g. favorable factors aside from Gle...